초록문의 abstract@kcsnet.or.kr

결제문의 member@kcsnet.or.kr

현재 가능한 작업은 아래와 같습니다.
  • 09월 04일 17시 이후 : 초록수정 불가능, 일정확인 및 검색만 가능

제114회 대한화학회 학술발표회, 총회 및 기기전시회 안내 Comparison of delivery efficiency of doxorubicin intercalated in RNA aptamer and the one encapsulated in RNA aptamer-conjugated liposome

2014년 9월 3일 15시 49분 26초
BIO.P-654 이곳을 클릭하시면 발표코드에 대한 설명을 보실 수 있습니다.
10월 15일 (수요일) 16:00~19:00
저자 및
백시은, 김동은*
건국대학교 생명공학과, Korea
Combination of drug delivery and specific targeting has potentials for treating cancer diseases. To achieve this goal, specific ligands targeting cancer cells and bioconjugate vehicles for drug delivery are necessary. Liposomes are one of successful drug-delivery materials because they can reduce toxicity and enhance stable drug delivery by encapsulation of drugs. They are composed of a lipid bilayer, which can fuse with the cell membrane. Aptamers are single-stranded nucleic acid that can bind to target molecules with high affinity and specificity. RNA aptamer has been used as drug delivery material targeting the tumor, in which anti-cancer drug was intercalated in aptamer. For example, prostate cancer cells expressing prostate-specific membrane antigen (PSMA) have been targeted for specific delivery of doxorubicin (Dox) with PSMA RNA aptamer. In our study, we compared two methods for Dox delivery to the PSMA (+) cancer cells, which are intercalation of Dox into the aptamer (Apt-Dox) and encapsulation of Dox in the aptamer-conjugated liposome (termed as “aptamosome”). Based on results regarding specificity and Dox delivery efficiency toward PSMA(+) cancer cells, aptamosomes encapsulating Dox (Apm-Dox) was superior to Apt-Dox. Thus, we demonstrated that anti-cancer drug Dox is safely encapsulated in the aptamosome which specifically targets the PSMA(+) prostate cancer cells.